Loading...
73 Changes in Palivizumab usage in Canada 2005–2017 (Data from CARESS registry)
BACKGROUND: Palivizumabis a monoclonal antibody for preventionof serious lower respiratory tract infection caused by respiratory syncytial virus (RSV) in high risk children. Safety and efficacy were established in infants with bronchopulmonary dysplasia (BPD), prematurity (≤ 35 weeks gestational age...
Na minha lista:
| Udgivet i: | Paediatr Child Health |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2019
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6543311/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/pch/pxz066.072 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|